Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$119.79 USD

119.79
2,009,823

+0.19 (0.16%)

Updated Dec 1, 2021 04:05 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (181 out of 254)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Should You Buy?

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) to Post Q2 Earnings: What's in the Offing?

McKesson's (MCK) fiscal second-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

OPKO Health (OPK) to Report Q3 Earnings: What's in Store?

OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.

Livongo Health (LVGO) to Post Q3 Earnings: What's in Store?

Livongo Health's (LVGO) third-quarter results are likely to reflect growth in core Livongo for Diabetes solution.

Baxter (BAX) to Report Q3 Earnings: What's in the Cards?

Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Here's Why You Should Add Globus Medical to Your Portfolio

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Debanjana Dey headshot

4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus

Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

3 Coronavirus-Led Threats to MedTech That May Linger

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of 106.94% and 31.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?

Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.

Sriparna Ghosal headshot

3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis

Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.

Debanjana Dey headshot

3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest

Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.

Sriparna Ghosal headshot

3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs

Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.

Trina Mukherjee headshot

Medical Products Industry's Near-Term Outlook Lacks Spark

AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.

Zimmer Biomet Adds New Features to mymobility with Apple Watch

Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.

The Smart Future: Will Robotics Call the Shots Post Coronavirus?

Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.